EyePoint Pharmaceuticals (NASDAQ:EYPT) announced the appointment of Ramiro Ribeiro as Chief Medical Officer.

EyePoint Pharmaceuticals（纳斯达克：EYPT）宣布任命拉米罗·里贝罗为首席医疗官。

Ribeiro succeeds Dario Paggiarino who has served as EyePoint’s Chief Medical Officer since 2016.

里贝罗接替达里奥·帕吉亚里诺（DarioPaggiarino），达里奥·帕吉亚里诺自2016年以来一直担任EyePoint的首席医疗官。

Ribeiro joins EyePoint from Apellis Pharmaceuticals, where he served as Vice President, Head of Clinical Development. Source: Press Release

里贝罗加入了来自阿佩利斯制药公司的EyePoint，在那里他担任副总裁兼临床开发负责人。来源：新闻稿

More on EyePoint Pharmaceuticals EyePoint Is Betting The Bank On EYP-1901 EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal JP Morgan starts EyePoint at overweight, cites eye drug potential EyePoint Pharmaceuticals prices upsized $200 million stock offering .

更多关于EyePoint Pharmaceuticals的信息EyePoint将银行押注于EYP-1901 EyePoint Pharmaceuticals：创新眼部治疗，但此时“持有”EyePoint Pharmaceuticals因湿性AMD而飙升研究结果：Durasert看起来是真正的交易JP Morgan开始增持EyePoint，引用EyePoint Pharmaceuticals潜在价格上调2亿美元的股票发行。